New pill aims to clean iron from organs in blood disorder patients

NCT ID NCT05693909

Recruiting now Disease control Sponsor: Pharmacosmos A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests an oral drug called SP-420 in about 90 adults with transfusion-dependent β-thalassemia or low-risk myelodysplastic syndromes (MDS). The goal is to see how well SP-420 removes excess iron from the liver and other organs, and whether it is safe. Participants take the drug three times a week and undergo MRI scans to measure iron levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SP-420 (an oral iron chelator)
What this could lead to: If successful, SP-420 could offer a new oral option to safely reduce iron buildup from frequent blood transfusions, potentially lowering organ damage risk.
What could go wrong: This is an early Phase 2 trial with only 90 participants, so results may not apply broadly. The drug may cause side effects or fail to clear iron effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA THALASSEMIA MAJOR ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta-thalassemia major myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BETA THALASSEMIA MAJOR ANEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Pharmacosmos Investigational Site
RECRUITING

Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.